Health
Clinical trial testing efficacy of antibody against SARS-CoV-2 begins – Medical Xpress
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
For the BLAZE-1 trial, UChicago is recruiting 22 participants to be treated with the LY-CoV555 antibody developed by Eli Lilly and Company in collaboration with AbCellera. The antibody was first identified by scientists at the National Institute of Allergy and Infectious Diseases and AbCe…
-
Noosa News23 hours agoWhy Brisbane needs to (re)embrace Los Angeles
-
General23 hours agoAustralia retains Chappell-Hadlee Trophy after rain washes out second T20I against New Zealand
-
General22 hours agoUK names Sarah Mullally as first female Archbishop of Canterbury to lead Church of England
-
General22 hours agoSussan Ley responds to Andrew Hastie’s Shadow Cabinet resignation